Abstract
Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) is a tumor suppressor that antagonizes the phosphatidylinositol-3-kinase (PI3K)/Akt/mTOR pathway by functioning as a lipid phosphatase. This ubiquitous and evolutionarily conserved signaling cascade influences numerous functions including cell growth, survival, proliferation, migration and metabolism. Inherited mutations in PTEN cause pleiotropic effects including cancer predisposition as well as a range of neurological abnormalities revealing specialized roles for PTEN in nervous system development and maintenance. Somatic mutations in PTEN occur frequently as late events in sporadic brain tumors. Mouse models based on Pten deletion in the brain have provided insights into the normal functions of Pten in the nervous system as well as the initiation and progression of gliomas. Compromised PTEN function may contribute to gliomagenesis through disrupted regulation of proliferation, migration, invasion, angiogenesis, stem cell self-renewal and regulation of other tumor suppressor pathways such as p53. Clinical findings in high-grade glioma suggest that PTEN gene alterations are associated with poor prognosis and may influence response to specific therapies. Emerging research using specific pharmacological inhibitors of the PI3K pathway may provide novel therapeutic options for the treatment of PTEN-deficient tumors.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abel TW, Baker SJ, Fraser MM, Tihan T, Nelson JS, Yachnis AT et al. (2005). Lhermitte-Duclos disease: a report of 31 cases with immunohistochemical analysis of the PTEN/AKT/mTOR pathway. J Neuropathol Exp Neurol 64: 341–349.
Alessi DR, James SR, Downes CP, Holmes AB, Gaffney PR, Reese CB et al. (1997). Characterization of a 3-phosphoinositide-dependent protein kinase which phosphorylates and activates protein kinase Balpha. Curr Biol 7: 261–269.
Backman SA, Stambolic V, Suzuki A, Haight J, Elia A, Pretorius J et al. (2001). Deletion of Pten in mouse brain causes seizures, ataxia and defects in soma size resembling Lhermitte-Duclos disease. Nat Genet 29: 396–403.
Baeza N, Weller M, Yonekawa Y, Kleihues P, Ohgaki H . (2003). PTEN methylation and expression in glioblastomas. Acta Neuropathol 106: 479–485.
Balendran A, Currie R, Armstrong CG, Avruch J, Alessi DR . (1999). Evidence that 3-phosphoinositide-dependent protein kinase-1 mediates phosphorylation of p70 S6 kinase in vivo at Thr-412 as well as Thr-252. J Biol Chem 274: 37400–37406.
Bao S, Wu Q, McLendon RE, Hao Y, Shi Q, Hjelmeland AB et al. (2006). Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444: 756–760.
Bellacosa A, de Feo D, Godwin AK, Bell DW, Cheng JQ, Altomare DA et al. (1995). Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas. Int J Cancer 64: 280–285.
Bianco R, Shin I, Ritter CA, Yakes FM, Basso A, Rosen N et al. (2003). Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the antitumor action of EGFR tyrosine kinase inhibitors. Oncogene 22: 2812–2822.
Bigner SH, Vogelstein B . (1990). Cytogenetics and molecular genetics of malignant gliomas and medulloblastoma. Brain Pathol 1: 12–18.
Bjornsti MA, Houghton PJ . (2004). The TOR pathway: a target for cancer therapy. Nat Rev Cancer 4: 335–348.
Boland E, Clayton-Smith J, Woo VG, McKee S, Manson FD, Medne L et al. (2007). Mapping of deletion and translocation breakpoints in 1q44 implicates the serine/threonine kinase AKT3 in postnatal microcephaly and agenesis of the corpus callosum. Am J Hum Genet 81: 292–303.
Broderick DK, Di C, Parrett TJ, Samuels YR, Cummins JM, McLendon RE et al. (2004). Mutations of PIK3CA in anaplastic oligodendrogliomas, high-grade astrocytomas, and medulloblastomas. Cancer Res 64: 5048–5050.
Brognard J, Sierecki E, Gao T, Newton AC . (2007). PHLPP and a second isoform, PHLPP2, differentially attenuate the amplitude of Akt signaling by regulating distinct Akt isoforms. Mol Cell 25: 917–931.
Brunet A, Bonni A, Zigmond MJ, Lin MZ, Juo P, Hu LS et al. (1999). Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell 96: 857–868.
Butler MG, Dasouki MJ, Zhou XP, Talebizadeh Z, Brown M, Takahashi TN et al. (2005). Subset of individuals with autism spectrum disorders and extreme macrocephaly associated with germline PTEN tumour suppressor gene mutations. J Med Genet 42: 318–321.
Chakravarti A, Delaney MA, Noll E, Black PM, Loeffler JS, Muzikansky A et al. (2001). Prognostic and pathologic significance of quantitative protein expression profiling in human gliomas. Clin Cancer Res 7: 2387–2395.
Chang CJ, Freeman DJ, Wu H . (2004). PTEN regulates Mdm2 expression through the P1 promoter. J Biol Chem 279: 29841–29848.
Chen ML, Xu PZ, Peng XD, Chen WS, Guzman G, Yang X et al. (2006). The deficiency of Akt1 is sufficient to suppress tumor development in Pten+/− mice. Genes Dev 20: 1569–1574.
Chen WS, Xu PZ, Gottlob K, Chen ML, Sokol K, Shiyanova T et al. (2001). Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. Genes Dev 15: 2203–2208.
Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725–730.
Cheng JQ, Ruggeri B, Klein WM, Sonoda G, Altomare DA, Watson DK et al. (1996). Amplification of AKT2 in human pancreatic cells and inhibition of AKT2 expression and tumorigenicity by antisense RNA. Proc Natl Acad Sci USA 93: 3636–3641.
Cho H, Mu J, Kim JK, Thorvaldsen JL, Chu Q, Crenshaw III EB et al. (2001a). Insulin resistance and a diabetes mellitus-like syndrome in mice lacking the protein kinase Akt2 (PKB beta). Science 292: 1728–1731.
Cho H, Thorvaldsen JL, Chu Q, Feng F, Birnbaum MJ . (2001b). Akt1/PKBalpha is required for normal growth but dispensable for maintenance of glucose homeostasis in mice. J Biol Chem 276: 38349–38352.
Chow LM, Baker SJ . (2006). PTEN function in normal and neoplastic growth. Cancer Lett 241: 184–196.
Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S et al. (2008). Antitumor activity of rapamycin in a phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med 5: e8.
Dey N, Crosswell HE, De P, Parsons R, Peng Q, Su JD et al. (2008). The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res 68: 1862–1871.
Di Cristofano A, De Acetis M, Koff A, Cordon-Cardo C, Pandolfi PP . (2001). Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat Genet 27: 222–224.
Dijkers PF, Birkenkamp KU, Lam EW, Thomas NS, Lammers JW, Koenderman L et al. (2002). FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: protein kinase B-enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol 156: 531–542.
Ding H, Roncari L, Shannon P, Wu X, Lau N, Karaskova J et al. (2001). Astrocyte-specific expression of activated p21-ras results in malignant astrocytoma formation in a transgenic mouse model of human gliomas. Cancer Res 61: 3826–3836.
Easton RM, Cho H, Roovers K, Shineman DW, Mizrahi M, Forman MS et al. (2005). Role for Akt3/protein kinase Bgamma in attainment of normal brain size. Mol Cell Biol 25: 1869–1878.
Eng C . (2003). PTEN: one gene, many syndromes. Hum Mutat 22: 183–198.
Engelman JA, Luo J, Cantley LC . (2006). The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism. Nat Rev Genet 7: 606–619.
Ermoian RP, Furniss CS, Lamborn KR, Basila D, Berger MS, Gottschalk AR et al. (2002). Dysregulation of PTEN and protein kinase B is associated with glioma histology and patient survival. Clin Cancer Res 8: 1100–1106.
Fan QW, Cheng CK, Nicolaides TP, Hackett CS, Knight ZA, Shokat KM et al. (2007). A dual phosphoinositide-3-kinase alpha/mTOR inhibitor cooperates with blockade of epidermal growth factor receptor in PTEN-mutant glioma. Cancer Res 67: 7960–7965.
Fan QW, Knight ZA, Goldenberg DD, Yu W, Mostov KE, Stokoe D et al. (2006). A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9: 341–349.
Folkman J . (2006). Angiogenesis. Annu Rev Med 57: 1–18.
Fraser MM, Bayazitov IT, Zakharenko SS, Baker SJ . (2008). Phosphatase and tensin homolog, deleted on chromosome 10 deficiency in brain causes defects in synaptic structure, transmission and plasticity, and myelination abnormalities. Neuroscience 151: 476–488.
Fraser MM, Zhu X, Kwon CH, Uhlmann EJ, Gutmann DH, Baker SJ . (2004). Pten loss causes hypertrophy and increased proliferation of astrocytes in vivo. Cancer Res 64: 7773–7779.
Freeman DJ, Li AG, Wei G, Li HH, Kertesz N, Lesche R et al. (2003). PTEN tumor suppressor regulates p53 protein levels and activity through phosphatase-dependent and -independent mechanisms. Cancer Cell 3: 117–130.
Furnari FB, Huang HJ, Cavenee WK . (1998). The phosphoinositol phosphatase activity of PTEN mediates a serum-sensitive G1 growth arrest in glioma cells. Cancer Res 58: 5002–5008.
Goffin A, Hoefsloot LH, Bosgoed E, Swillen A, Fryns JP . (2001). PTEN mutation in a family with Cowden syndrome and autism. Am J Med Genet 105: 521–524.
Gottschalk AR, Basila D, Wong M, Dean NM, Brandts CH, Stokoe D et al. (2001). p27Kip1 is required for PTEN-induced G1 growth arrest. Cancer Res 61: 2105–2111.
Goudar RK, Shi Q, Hjelmeland MD, Keir ST, McLendon RE, Wikstrand CJ et al. (2005). Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition. Mol Cancer Ther 4: 101–112.
Groszer M, Erickson R, Scripture-Adams DD, Dougherty JD, Le Belle J, Zack JA et al. (2006). PTEN negatively regulates neural stem cell self-renewal by modulating G0-G1 cell cycle entry. Proc Natl Acad Sci USA 103: 111–116.
Groszer M, Erickson R, Scripture-Adams DD, Lesche R, Trumpp A, Zack JA et al. (2001). Negative regulation of neural stem/progenitor cell proliferation by the Pten tumor suppressor gene in vivo. Science 294: 2186–2189.
Gustafson S, Zbuk KM, Scacheri C, Eng C . (2007). Cowden syndrome. Semin Oncol 34: 428–434.
Hambardzumyan D, Becher OJ, Rosenblum MK, Pandolfi PP, Manova-Todorova K, Holland EC . (2008). PI3K pathway regulates survival of cancer stem cells residing in the perivascular niche following radiation in medulloblastoma in vivo. Genes Dev 22: 436–448.
Hartmann C, Bartels G, Gehlhaar C, Holtkamp N, von Deimling A . (2005a). PIK3CA mutations in glioblastoma multiforme. Acta Neuropathol 109: 639–642.
Hartmann W, Digon-Sontgerath B, Koch A, Waha A, Endl E, Dani I et al. (2006). Phosphatidylinositol 3′-kinase/AKT signaling is activated in medulloblastoma cell proliferation and is associated with reduced expression of PTEN. Clin Cancer Res 12: 3019–3027.
Hartmann W, Koch A, Brune H, Waha A, Schuller U, Dani I et al. (2005b). Insulin-like growth factor II is involved in the proliferation control of medulloblastoma and its cerebellar precursor cells. Am J Pathol 166: 1153–1162.
Hayes MP, Wang H, Espinal-Witter R, Douglas W, Solomon GJ, Baker SJ et al. (2006). PIK3CA and PTEN mutations in uterine endometrioid carcinoma and complex atypical hyperplasia. Clin Cancer Res 12: 5932–5935.
Hemminki A, Markie D, Tomlinson I, Avizienyte E, Roth S, Loukola A et al. (1998). A serine/threonine kinase gene defective in Peutz–Jeghers syndrome. Nature 391: 184–187.
Hoekman MF, Jacobs FM, Smidt MP, Burbach JP . (2006). Spatial and temporal expression of FoxO transcription factors in the developing and adult murine brain. Gene Expr Patterns 6: 134–140.
Holland EC, Celestino J, Dai C, Schaefer L, Sawaya RE, Fuller GN . (2000). Combined activation of Ras and Akt in neural progenitors induces glioblastoma formation in mice. Nat Genet 25: 55–57.
Homma T, Fukushima T, Vaccarella S, Yonekawa Y, Di Patre PL, Franceschi S et al. (2006). Correlation among pathology, genotype, and patient outcomes in glioblastoma. J Neuropathol Exp Neurol 65: 846–854.
Horie Y, Suzuki A, Kataoka E, Sasaki T, Hamada K, Sasaki J et al. (2004). Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J Clin Invest 113: 1774–1783.
Hu X, Pandolfi PP, Li Y, Koutcher JA, Rosenblum M, Holland EC . (2005). mTOR promotes survival and astrocytic characteristics induced by Pten/AKT signaling in glioblastoma. Neoplasia 7: 356–368.
Hunter C, Smith R, Cahill DP, Stephens P, Stevens C, Teague J et al. (2006). A hypermutation phenotype and somatic MSH6 mutations in recurrent human malignant gliomas after alkylator chemotherapy. Cancer Res 66: 3987–3991.
Iida S, Tanaka Y, Fujii H, Hayashi S, Kimura M, Nagareda T et al. (1998). A heterozygous frameshift mutation of the PTEN/MMAC1 gene in a patient with Lhermitte-Duclos disease—only the mutated allele was expressed in the cerebellar tumor. Int J Mol Med 1: 925–929.
Inoki K, Li Y, Zhu T, Wu J, Guan KL . (2002). TSC2 is phosphorylated and inhibited by Akt and suppresses mTOR signalling. Nat Cell Biol 4: 648–657.
Jones G, Machado Jr J, Tolnay M, Merlo A . (2001). PTEN-independent induction of caspase-mediated cell death and reduced invasion by the focal adhesion targeting domain (FAT) in human astrocytic brain tumors which highly express focal adhesion kinase (FAK). Cancer Res 61: 5688–5691.
Katajisto P, Vallenius T, Vaahtomeri K, Ekman N, Udd L, Tiainen M et al. (2007). The LKB1 tumor suppressor kinase in human disease. Biochim Biophys Acta 1775: 63–75.
Knobbe CB, Reifenberger G . (2003). Genetic alterations and aberrant expression of genes related to the phosphatidyl-inositol-3′-kinase/protein kinase B (Akt) signal transduction pathway in glioblastomas. Brain Pathol 13: 507–518.
Kops GJ, Medema RH, Glassford J, Essers MA, Dijkers PF, Coffer PJ et al. (2002). Control of cell cycle exit and entry by protein kinase B-regulated forkhead transcription factors. Mol Cell Biol 22: 2025–2036.
Koul D, Parthasarathy R, Shen R, Davies MA, Jasser SA, Chintala SK et al. (2001). Suppression of matrix metalloproteinase-2 gene expression and invasion in human glioma cells by MMAC/PTEN. Oncogene 20: 6669–6678.
Kraus JA, Glesmann N, Beck M, Krex D, Klockgether T, Schackert G et al. (2000). Molecular analysis of the PTEN, TP53 and CDKN2A tumor suppressor genes in long-term survivors of glioblastoma multiforme. J Neurooncol 48: 89–94.
Kubiatowski T, Jang T, Lachyankar MB, Salmonsen R, Nabi RR, Quesenberry PJ et al. (2001). Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J Neurosurg 95: 480–488.
Kwon CH, Luikart BW, Powell CM, Zhou J, Matheny SA, Zhang W et al. (2006). Pten regulates neuronal arborization and social interaction in mice. Neuron 50: 377–388.
Kwon CH, Zhu X, Zhang J, Knoop LL, Tharp R, Smeyne RJ et al. (2001). Pten regulates neuronal soma size: a mouse model of Lhermitte-Duclos disease. Nat Genet 29: 404–411.
Lachlan KL, Lucassen AM, Bunyan D, Temple IK . (2007). Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome represent one condition with variable expression and age-related penetrance: results of a clinical study of PTEN mutation carriers. J Med Genet 44: 579–585.
Lee J, Kotliarova S, Kotliarov Y, Li A, Su Q, Donin NM et al. (2006). Tumor stem cells derived from glioblastomas cultured in bFGF and EGF more closely mirror the phenotype and genotype of primary tumors than do serum-cultured cell lines. Cancer Cell 9: 391–403.
Lein ES, Hawrylycz MJ, Ao N, Ayres M, Bensinger A, Bernard A et al. (2007). Genome-wide atlas of gene expression in the adult mouse brain. Nature 445: 168–176.
Leslie NR, Yang X, Downes CP, Weijer CJ . (2007). PtdIns(3,4,5)P(3)-dependent and -independent roles for PTEN in the control of cell migration. Curr Biol 17: 115–125.
Li DM, Sun H . (1997). TEP1, encoded by a candidate tumor suppressor locus, is a novel protein tyrosine phosphatase regulated by transforming growth factor beta. Cancer Res 57: 2124–2129.
Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang SI et al. (1997). PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science 275: 1943–1947.
Li L, Liu F, Salmonsen RA, Turner TK, Litofsky NS, Di Cristofano A et al. (2002). PTEN in neural precursor cells: regulation of migration, apoptosis, and proliferation. Mol Cell Neurosci 20: 21–29.
Liang J, Zubovitz J, Petrocelli T, Kotchetkov R, Connor MK, Han K et al. (2002). PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat Med 8: 1153–1160.
Liliental J, Moon SY, Lesche R, Mamillapalli R, Li D, Zheng Y et al. (2000). Genetic deletion of the Pten tumor suppressor gene promotes cell motility by activation of Rac1 and Cdc42 GTPases. Curr Biol 10: 401–404.
Lin H, Bondy ML, Langford LA, Hess KR, Delclos GL, Wu X et al. (1998). Allelic deletion analyses of MMAC/PTEN and DMBT1 loci in gliomas: relationship to prognostic significance. Clin Cancer Res 4: 2447–2454.
Louis DN, Ohgaki H, Wiestler OD, Cavenee WK (eds) (2007). WHO Classification of Tumours of the Central Nervous System. Internationa Agency for Research on Cancer: Lyon.
Maehama T, Dixon JE . (1998). The tumor suppressor, PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3, 4, 5-trisphosphate. J Biol Chem 273: 13375–13378.
Maier D, Jones G, Li X, Schonthal AH, Gratzl O, Van Meir EG et al. (1999). The PTEN lipid phosphatase domain is not required to inhibit invasion of glioma cells. Cancer Res 59: 5479–5482.
Maity A, Pore N, Lee J, Solomon D, O'Rourke DM . (2000). Epidermal growth factor receptor transcriptionally up-regulates vascular endothelial growth factor expression in human glioblastoma cells via a pathway involving phosphatidylinositol 3′-kinase and distinct from that induced by hypoxia. Cancer Res 60: 5879–5886.
Marino S, Krimpenfort P, Leung C, van der Korput HA, Trapman J, Camenisch I et al. (2002). PTEN is essential for cell migration but not for fate determination and tumourigenesis in the cerebellum. Development 129: 3513–3522.
Maroulakou IG, Oemler W, Naber SP, Tsichlis PN . (2007). Akt1 ablation inhibits, whereas Akt2 ablation accelerates, the development of mammary adenocarcinomas in mouse mammary tumor virus (MMTV)-ErbB2/neu and MMTV-polyoma middle T transgenic mice. Cancer Res 67: 167–177.
Mayo LD, Dixon JE, Durden DL, Tonks NK, Donner DB . (2002). PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem 277: 5484–5489.
Medema RH, Kops GJ, Bos JL, Burgering BM . (2000). AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1. Nature 404: 782–787.
Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ et al. (2005). Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med 353: 2012–2024.
Modur V, Nagarajan R, Evers BM, Milbrandt J . (2002). FOXO proteins regulate tumor necrosis factor-related apoptosis inducing ligand expression. Implications for PTEN mutation in prostate cancer. J Biol Chem 277: 47928–47937.
Myers MP, Pass I, Batty IH, Van der Kaay J, Stolarov JP, Hemmings BA et al. (1998). The lipid phosphatase activity of PTEN is critical for its tumor supressor function. Proc Natl Acad Sci USA 95: 13513–13518.
Myers MP, Stolarov JP, Eng C, Li J, Wang SI, Wigler MH et al. (1997). P-TEN, the tumor suppressor from human chromosome 10q23, is a dual-specificity phosphatase. Proc Natl Acad Sci USA 94: 9052–9057.
Nagata Y, Lan KH, Zhou X, Tan M, Esteva FJ, Sahin AA et al. (2004). PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell 6: 117–127.
Nakayama K, Nakayama N, Kurman RJ, Cope L, Pohl G, Samuels Y et al. (2006). Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms. Cancer Biol Ther 5: 779–785.
O'Reilly KE, Rojo F, She QB, Solit D, Mills GB, Smith D et al. (2006). mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. Cancer Res 66: 1500–1508.
Oda K, Stokoe D, Taketani Y, McCormick F . (2005). High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma. Cancer Res 65: 10669–10673.
Ohgaki H, Dessen P, Jourde B, Horstmann S, Nishikawa T, Di Patre PL et al. (2004). Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892–6899.
Pedrero JM, Carracedo DG, Pinto CM, Zapatero AH, Rodrigo JP, Nieto CS et al. (2005). Frequent genetic and biochemical alterations of the PI 3-K/AKT/PTEN pathway in head and neck squamous cell carcinoma. Int J Cancer 114: 242–248.
Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD et al. (2006). Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 9: 157–173.
Pore N, Jiang Z, Shu HK, Bernhard E, Kao GD, Maity A . (2006). Akt1 activation can augment hypoxia-inducible factor-1alpha expression by increasing protein translation through a mammalian target of rapamycin-independent pathway. Mol Cancer Res 4: 471–479.
Prados MD, Lamborn KR, Chang S, Burton E, Butowski N, Malec M et al. (2006). Phase 1 study of erlotinib HCl alone and combined with temozolomide in patients with stable or recurrent malignant glioma. Neuro Oncol 8: 67–78.
Pu P, Kang C, Li J, Jiang H, Cheng J . (2006). The effects of antisense AKT2 RNA on the inhibition of malignant glioma cell growth in vitro and in vivo. J Neurooncol 76: 1–11.
Raffel C, Frederick L, O'Fallon JR, Atherton-Skaff P, Perry A, Jenkins RB et al. (1999). Analysis of oncogene and tumor suppressor gene alterations in pediatric malignant astrocytomas reveals reduced survival for patients with PTEN mutations. Clin Cancer Res 5: 4085–4090.
Raftopoulou M, Etienne-Manneville S, Self A, Nicholls S, Hall A . (2004). Regulation of cell migration by the C2 domain of the tumor suppressor PTEN. Science 303: 1179–1181.
Rao G, Pedone CA, Del Valle L, Reiss K, Holland EC, Fults DW . (2004). Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23: 6156–6162.
Rasheed BK, Stenzel TT, McLendon RE, Parsons R, Friedman AH, Friedman HS et al. (1997). PTEN gene mutations are seen in high-grade but not in low-grade gliomas. Cancer Res 57: 4187–4190.
Raynaud FI, Eccles S, Clarke PA, Hayes A, Nutley B, Alix S et al. (2007). Pharmacologic characterization of a potent inhibitor of class I phosphatidylinositide 3-kinases. Cancer Res 67: 5840–5850.
Rich JN, Hans C, Jones B, Iversen ES, McLendon RE, Rasheed BK et al. (2005). Gene expression profiling and genetic markers in glioblastoma survival. Cancer Res 65: 4051–4058.
Rich JN, Reardon DA, Peery T, Dowell JM, Quinn JA, Penne KL et al. (2004). Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22: 133–142.
Rickert CH, Paulus W . (2004). Comparative genomic hybridization in central and peripheral nervous system tumors of childhood and adolescence. J Neuropathol Exp Neurol 63: 399–417.
Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S et al. (2004). High frequency of mutations of the PIK3CA gene in human cancers. Science 304: 554.
Sano T, Lin H, Chen X, Langford LA, Koul D, Bondy ML et al. (1999). Differential expression of MMAC/PTEN in glioblastoma multiforme: relationship to localization and prognosis. Cancer Res 59: 1820–1824.
Sarbassov DD, Guertin DA, Ali SM, Sabatini DM . (2005). Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307: 1098–1101.
Schlegel J, Piontek G, Mennel HD . (2002). Activation of the anti-apoptotic Akt/protein kinase B pathway in human malignant gliomas in vivo. Anticancer Res 22: 2837–2840.
Shannon P, Sabha N, Lau N, Kamnasaran D, Gutmann DH, Guha A . (2005). Pathological and molecular progression of astrocytomas in a GFAP:12 V-Ha-Ras mouse astrocytoma model. Am J Pathol 167: 859–867.
Shaw RJ, Bardeesy N, Manning BD, Lopez L, Kosmatka M, DePinho RA et al. (2004). The LKB1 tumor suppressor negatively regulates mTOR signaling. Cancer Cell 6: 91–99.
Shaw RJ, Cantley LC . (2006). Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441: 424–430.
She QB, Solit DB, Ye Q, O'Reilly KE, Lobo J, Rosen N . (2005). The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell 8: 287–297.
Shin I, Yakes FM, Rojo F, Shin NY, Bakin AV, Baselga J et al. (2002). PKB/Akt mediates cell-cycle progression by phosphorylation of p27(Kip1) at threonine 157 and modulation of its cellular localization. Nat Med 8: 1145–1152.
Simpson L, Parsons R . (2001). PTEN: life as a tumor suppressor. Exp Cell Res 264: 29–41.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. (2004). Identification of human brain tumour initiating cells. Nature 432: 396–401.
Smith JS, Tachibana I, Passe SM, Huntley BK, Borell TJ, Iturria N et al. (2001). PTEN mutation, EGFR amplification, and outcome in patients with anaplastic astrocytoma and glioblastoma multiforme. J Natl Cancer Inst 93: 1246–1256.
Stahl M, Dijkers PF, Kops GJ, Lens SM, Coffer PJ, Burgering BM et al. (2002). The forkhead transcription factor FoxO regulates transcription of p27Kip1 and Bim in response to IL-2. J Immunol 168: 5024–5031.
Stambolic V, MacPherson D, Sas D, Lin Y, Snow B, Jang Y et al. (2001). Regulation of PTEN transcription by p53. Mol Cell 8: 317–325.
Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH et al. (1997). Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat Genet 15: 356–362.
Suzuki A, Itami S, Ohishi M, Hamada K, Inoue T, Komazawa N et al. (2003a). Keratinocyte-specific Pten deficiency results in epidermal hyperplasia, accelerated hair follicle morphogenesis and tumor formation. Cancer Res 63: 674–681.
Suzuki A, Kaisho T, Ohishi M, Tsukio-Yamaguchi M, Tsubata T, Koni PA et al. (2003b). Critical roles of Pten in B cell homeostasis and immunoglobulin class switch recombination. J Exp Med 197: 657–667.
Suzuki A, Yamaguchi MT, Ohteki T, Sasaki T, Kaisho T, Kimura Y et al. (2001). T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14: 523–534.
Tada K, Shiraishi S, Kamiryo T, Nakamura H, Hirano H, Kuratsu J et al. (2001). Analysis of loss of heterozygosity on chromosome 10 in patients with malignant astrocytic tumors: correlation with patient age and survival. J Neurosurg 95: 651–659.
Tamura M, Gu J, Matsumoto K, Aota S, Parsons R, Yamada KM . (1998). Inhibition of cell migration, spreading, and focal adhesions by tumor suppressor PTEN. Science 280: 1614–1617.
Tohma Y, Gratas C, Biernat W, Peraud A, Fukuda M, Yonekawa Y et al. (1998). PTEN (MMAC1) mutations are frequent in primary glioblastomas (de novo) but not in secondary glioblastomas. J Neuropathol Exp Neurol 57: 684–689.
Tschopp O, Yang ZZ, Brodbeck D, Dummler BA, Hemmings-Mieszczak M, Watanabe T et al. (2005). Essential role of protein kinase B gamma (PKB gamma/Akt3) in postnatal brain development but not in glucose homeostasis. Development 132: 2943–2954.
Uhlmann EJ, Li W, Scheidenhelm DK, Gau CL, Tamanoi F, Gutmann DH . (2004). Loss of tuberous sclerosis complex 1 (Tsc1) expression results in increased Rheb/S6K pathway signaling important for astrocyte cell size regulation. Glia 47: 180–188.
Um SH, Frigerio F, Watanabe M, Picard F, Joaquin M, Sticker M et al. (2004). Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity. Nature 431: 200–205.
van Diepen MT, Eickholt BJ . (2008). Function of PTEN during the formation and maintenance of neuronal circuits in the brain. Dev Neurosci 30: 59–64.
Viglietto G, Motti ML, Bruni P, Melillo RM, D'Alessio A, Califano D et al. (2002). Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27(Kip1) by PKB/Akt-mediated phosphorylation in breast cancer. Nat Med 8: 1136–1144.
Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM et al. (2006). Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res 66: 7864–7869.
Wei Q, Clarke L, Scheidenhelm DK, Qian B, Tong A, Sabha N et al. (2006). High-grade glioma formation results from postnatal pten loss or mutant epidermal growth factor receptor expression in a transgenic mouse glioma model. Cancer Res 66: 7429–7437.
Wen S, Stolarov J, Myers MP, Su JD, Wigler MH, Tonks NK et al. (2001). PTEN controls tumor-induced angiogenesis. Proc Natl Acad Sci USA 98: 4622–4627.
Wiencke JK, Zheng S, Jelluma N, Tihan T, Vandenberg S, Tamguney T et al. (2007). Methylation of the PTEN promoter defines low-grade gliomas and secondary glioblastoma. Neuro Oncol 9: 271–279.
Xiao A, Wu H, Pandolfi PP, Louis DN, Van Dyke T . (2002). Astrocyte inactivation of the pRb pathway predisposes mice to malignant astrocytoma development that is accelerated by PTEN mutation. Cancer Cell 1: 157–168.
Xiao A, Yin C, Yang C, Di Cristofano A, Pandolfi PP, Van Dyke T . (2005). Somatic induction of Pten loss in a preclinical astrocytoma model reveals major roles in disease progression and avenues for target discovery and validation. Cancer Res 65: 5172–5180.
Yang ZZ, Tschopp O, Di-Poi N, Bruder E, Baudry A, Dummler B et al. (2005). Dosage-dependent effects of Akt1/protein kinase Balpha (PKBalpha) and Akt3/PKBgamma on thymus, skin, and cardiovascular and nervous system development in mice. Mol Cell Biol 25: 10407–10418.
Yilmaz OH, Valdez R, Theisen BK, Guo W, Ferguson DO, Wu H et al. (2006). Pten dependence distinguishes haematopoietic stem cells from leukaemia-initiating cells. Nature 441: 475–482.
Young J, Povey S . (1998). The genetic basis of tuberous sclerosis. Mol Med Today 4: 313–319.
Yue Q, Groszer M, Gil JS, Berk AJ, Messing A, Wu H et al. (2005). PTEN deletion in Bergmann glia leads to premature differentiation and affects laminar organization. Development 132: 3281–3291.
Zeng LH, Ouyang Y, Gazit V, Cirrito JR, Jansen LA, Ess KC et al. (2007). Abnormal glutamate homeostasis and impaired synaptic plasticity and learning in a mouse model of tuberous sclerosis complex. Neurobiol Dis 28: 184–196.
Zhou J, Wulfkuhle J, Zhang H, Gu P, Yang Y, Deng J et al. (2007). Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance. Proc Natl Acad Sci USA 104: 16158–16163.
Zhou XP, Marsh DJ, Morrison CD, Chaudhury AR, Maxwell M, Reifenberger G et al. (2003). Germline inactivation of PTEN and dysregulation of the phosphoinositol-3-kinase/Akt pathway cause human Lhermitte-Duclos disease in adults. Am J Hum Genet 73: 1191–1198.
Zhu Y, Parada LF . (2002). The molecular and genetic basis of neurological tumours. Nat Rev Cancer 2: 616–626.
Zori RT, Marsh DJ, Graham GE, Marliss EB, Eng C . (1998). Germline PTEN mutation in a family with Cowden syndrome and Bannayan-Riley-Ruvalcaba syndrome. Am J Med Genet 80: 399–402.
Zundel W, Schindler C, Haas-Kogan D, Koong A, Kaper F, Chen E et al. (2000). Loss of PTEN facilitates HIF-1-mediated gene expression. Genes Dev 14: 391–396.
Acknowledgements
We thank members of the Baker laboratory for helpful comments and discussions. SJB is supported by grants from the National Institutes of Health and by the American Lebanese and Syrian Associated Charities of St Jude Children's Research Hospital.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Endersby, R., Baker, S. PTEN signaling in brain: neuropathology and tumorigenesis. Oncogene 27, 5416–5430 (2008). https://doi.org/10.1038/onc.2008.239
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2008.239
Keywords
This article is cited by
-
Overexpressing eukaryotic elongation factor 1 alpha (eEF1A) proteins to promote corticospinal axon repair after injury
Cell Death Discovery (2022)
-
Effects of Long-Term In Vitro Expansion on Genetic Stability and Tumor Formation Capacity of Stem Cells
Stem Cell Reviews and Reports (2022)
-
CircRNA NALCN acts as an miR-493-3p sponge to regulate PTEN expression and inhibit glioma progression
Cancer Cell International (2021)
-
PTEN in prefrontal cortex is essential in regulating depression-like behaviors in mice
Translational Psychiatry (2021)
-
Pten is a key intrinsic factor regulating raphe 5-HT neuronal plasticity and depressive behaviors in mice
Translational Psychiatry (2021)
